Systemic lupus erythematosus is associated with an increased risk for pulmonary manifestations, including ILD and pulmonary hypertension.

The trial will assess the therapy’s pharmacokinetics, pharmacodynamics and safety, as well as its impact on disease activity.

Cytokine networks exhibit dual functionality: they are essential regulators of immune homeostasis, yet paradoxically act as pathogenic drivers in diseases such as rheumatoid arthritis (RA), systemic ...

Children born to anti-Ro antibody-positive mothers do not exhibit a greater prevalence of allergic, neurodevelopmental, or autoimmune conditions.

Thermo Fisher Scientific Inc. TMO is slated to release first-quarter 2025 results on April 23, before market open. Thermo ...

Cullinan Therapeutics (CGEM) announced that the European Medicines Agency, EMA, approved the Company’s Clinical Trial Application, CTA, for ...

Shanghai Pharmaceuticals Holding Co. Ltd. has identified C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, ...

Fate Therapeutics FATE recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) ...

The Lupus Research Alliance (LRA) is proud to announce the recipients of this year’s Lupus Innovation Award (LIA), addressing many critical themes in lupus research including novel therapeutic ...

Systemic sclerosis, or scleroderma, causes the hardening of skin and connective tissues. Often, the disease harms other ...

Fate Therapeutics (NASDAQ:FATE) gets FDA RMAT designation for FT819, an experimental CAR T-cell therapy for lupus. Read more ...